The Pediatric Praziquantel Consortium was established in July 2012 by Merck KGaA, Darmstadt, Germany, Astellas, Swiss TPH and Lygature (formerly TI Pharma). At the beginning of 2014 Farmanguinhos and Simcyp joined the Consortium as full partners. Since the start, all partners have been working together efficiently to progress the project and to achieve its objective.
Together, the partners bring many different areas of expertise to the project:
Merck KGaA (Darmstadt, Germany) leads the program and provides expertise and support relating to PZQ, including internal resources from different areas needed for clinical development – drug product manufacturing; preclinical; clinical and regulatory. Also responsible for the development and manufacturing of the L-PZQ Active Pharmaceutical Ingredient (API).
Astellas Pharma Inc. (Japan) has developed the new pediatric PZQ formulations, and provides expert advice on clinical development in children, and pharmacokinetic modeling.
Swiss Tropical & Public Health Institute is a not-for-profit Institute internationally renowned for its research, services, teaching and training in global health. It contributes with extensive experience in helminths biological and pharmacological research; epidemiology; and clinical research in endemic regions.
Lygature, a Dutch not-for-profit foundation, acts as the independent coordinator of the Consortium, providing governance in terms of progress, finance and collaboration. Since 2006, Lygature has supported close to a hundred public-private partnerships in the field of life sciences & health, including poverty-related diseases.
Farmanguinhos, the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to addressing the production and distribution of new pediatric formulations in endemic countries.
Simcyp, a UK-based research company, provides pharmacokinetics modeling capabilities and expertise.
The Schistosomiasis Control Initiative at Imperial College London, has been working for 15 years to provide treatments against schistosomiasis and three soil-transmitted helminths to the rural poor in Sub-Saharan Africa and Yemen. SCI will work with the Pediatric Praziquantel Consortium to facilitate preparation and implementation of the Access and Delivery plan in schistosomiasis endemic countries, to ensure optimal use for the new pediatric praziquantel formulation.